Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Prostate Cancer

  Free Subscription

Articles published in Br J Radiol

Retrieve available abstracts of 65 articles:
HTML format

Single Articles

    February 2024
  1. PAN K, Yao F, Hong W, Xiao J, et al
    Multimodal radiomics based on 18F-Prostate-specific membrane antigen-1007 PET/CT and multiparametric MRI for prostate cancer extracapsular extension prediction.
    Br J Radiol. 2024;97:408-414.
    PubMed     Abstract available

  2. CHENG T, Li H
    Prediction of Gleason score in prostate cancer patients based on radiomic features of transrectal ultrasound images.
    Br J Radiol. 2024;97:415-421.
    PubMed     Abstract available

    January 2024
  3. GIACOMETTI V, Grey AC, McCann AJ, Prise KM, et al
    An objective measure of response on whole-body MRI in metastatic hormone sensitive prostate cancer treated with androgen deprivation therapy, external beam radiotherapy, and radium-223.
    Br J Radiol. 2024 Jan 24:tqae005. doi: 10.1093.
    PubMed     Abstract available

  4. ALI I, Rezk M, Hamouda D, Talaat O, et al
    Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate to high risk prostate cancer.
    Br J Radiol. 2024 Jan 23:tqae021. doi: 10.1093.
    PubMed     Abstract available

  5. WINTER JD, Reddy V, Li W, Craig T, et al
    Impact of technological advances in treatment planning, image guidance, and treatment delivery on target margin design for prostate cancer radiotherapy: an updated review.
    Br J Radiol. 2024;97:31-40.
    PubMed     Abstract available

  6. AGGARWAL P, Krishna Kumar RG, Das CJ, Kubihal V, et al
    Role of non-contrast CT component of prostate-specific membrane antigen PET/CT scan in the detection of peripheral zone prostate cancer.
    Br J Radiol. 2024;97:195-200.
    PubMed     Abstract available

  7. MURAKAMI Y, Kawahara D, Soyano T, Kozuka T, et al
    Dosiomics for intensity-modulated radiotherapy in patients with prostate cancer: survival analysis stratified by baseline prostate-specific antigen and Gleason grade group in a 2-institutional retrospective study.
    Br J Radiol. 2024;97:142-149.
    PubMed     Abstract available

  8. RAJENDRAN I, Lee KL, Thavaraja L, Barrett T, et al
    Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making.
    Br J Radiol. 2024;97:113-119.
    PubMed     Abstract available

  9. MUKHERJEE S, Papadopoulos D, Chari N, Ellis D, et al
    High-grade prostate cancer demonstrates preferential growth in the cranio-caudal axis and provides discrimination of disease grade in an MRI parametric model.
    Br J Radiol. 2024 Jan 4:tqad066. doi: 10.1093.
    PubMed     Abstract available

    September 2023
  10. KENDRICK J, Francis R, Hassan GM, Rowshanfarzad P, et al
    Prospective inter- and intra-tracer repeatability analysis of radiomics features in [(68)Ga]Ga-PSMA-11 and [(18)F]F-PSMA-1007 PET scans in metastatic prostate cancer.
    Br J Radiol. 2023 Sep 26:20221178. doi: 10.1259/bjr.20221178.
    PubMed     Abstract available

  11. CASTAGNOLI F, Doners R, Tunariu N, Messiou C, et al
    Relative fat fraction of malignant bone lesions from breast cancer, prostate cancer and myeloma are significantly lower than normal bone marrow and shows excellent interobserver agreement.
    Br J Radiol. 2023 Sep 26:20230240. doi: 10.1259/bjr.20230240.
    PubMed     Abstract available

  12. SOLIMAN M, Elfatairy K, Ellessy RMI, Velichko YS, et al
    The utility of [(18)F]Fluciclovine PET/CT in Evaluating Nonmetastatic Castrate Resistant Prostate Cancer Patients (nmCRPCp): Diagnostic performance and Impact on Management.
    Br J Radiol. 2023 Sep 26:20230414. doi: 10.1259/bjr.20230414.
    PubMed     Abstract available

  13. GREWAL H, Kedar R, Dhillon G, Sidhu G, et al
    SpaceOAR hydrogel complications in prostate cancer: Pictorial review.
    Br J Radiol. 2023 Sep 26:20230717. doi: 10.1259/bjr.20230717.
    PubMed     Abstract available

  14. DONNERS R, Candito A, Blackledge M, Rata M, et al
    Repeatability of quantitative individual lesion and total disease multiparametric whole-body MRI measurements in prostate cancer bone metastases.
    Br J Radiol. 2023 Sep 3:20230378. doi: 10.1259/bjr.20230378.
    PubMed     Abstract available

  15. YATES AH, Power JW, Dempsey PJ, Agnew A, et al
    SpaceOAR hydrogel distribution and early complications in patients undergoing radiation therapy for prostate cancer.
    Br J Radiol. 2023 Sep 3:20220947. doi: 10.1259/bjr.20220947.
    PubMed     Abstract available

    July 2023
  16. KUMASAKA S, Seki Y, Takayama H, Kumasaka Y, et al
    Predictive value of prostate calcification for future cancer occurrence: a retrospective long-term follow-up cohort study.
    Br J Radiol. 2023;96:20221110.
    PubMed     Abstract available

    June 2023
  17. KONG V, Dang J, Wan V, Rosewall T, et al
    The dosimetric underpinning of bladder filling criteria for prostate image-guided volumetric modulated arc therapy.
    Br J Radiol. 2023;96:20230020.
    PubMed     Abstract available

  18. MCNEICE JM, Sanilkumar N, Alexander SE, Talbot J, et al
    Prostate stereotactic body radiotherapy: quantifying intra-fraction motion and calculating margins using the new BIR geometric uncertainties in daily online IGRT recommendations.
    Br J Radiol. 2023;96:20220852.
    PubMed     Abstract available

    April 2023
  19. CLOITRE M, Valerio M, Mampuya A, Rakauskas A, et al
    Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.
    Br J Radiol. 2023;96:20220803.
    PubMed     Abstract available

    March 2023
  20. STEVENS W, Parchment-Smith C, Adiotomre E, Hulson O, et al
    Does including histological outcomes in a multiparametric MRI report improve prostate biopsy decision making?
    Br J Radiol. 2023 Mar 1:20220395. doi: 10.1259/bjr.20220395.
    PubMed     Abstract available

    February 2023
  21. BENIDIR T, Lone Z, Nguyen JK, Ward R, et al
    The combination of prostate MRI PI-RADS scoring system and a genomic classifier is associated with pelvic lymph node metastasis at the time of radical prostatectomy.
    Br J Radiol. 2023 Feb 6:20220663. doi: 10.1259/bjr.20220663.
    PubMed     Abstract available

  22. KLEIBURG F, Heijmen L, Gelderblom AJ, Kielbasa SM, et al
    Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas.
    Br J Radiol. 2023 Feb 2:20220886. doi: 10.1259/bjr.20220886.
    PubMed     Abstract available

    December 2022
  23. SHU X, Liu Y, Qiao X, Ai G, et al
    Radiomic-Based machine learning model for the accurate prediction of prostate cancer risk stratification.
    Br J Radiol. 2022 Dec 7:20220238. doi: 10.1259/bjr.20220238.
    PubMed     Abstract available

    July 2022
  24. LIU Y, Wang S, Xiang LH, Xu G, et al
    The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
    Br J Radiol. 2022 Jul 25:20220209. doi: 10.1259/bjr.20220209.
    PubMed     Abstract available

    May 2022
  25. MORI N, Mugikura S, Takase K
    The role of magnetic resonance imaging in prostate cancer patients on active surveillance.
    Br J Radiol. 2022 May 23:20220140. doi: 10.1259/bjr.20220140.

    March 2022
    The role for MRI-guided transurethral ultrasound ablation in the continuum of prostate cancer care.
    Br J Radiol. 2022;95:20210959.
    PubMed     Abstract available

  27. FUTTERER JJ, Kim CK, Margolis DJ
    Innovations in prostate cancer: introductory editorial.
    Br J Radiol. 2022;95:20229003.

  28. WANG L, Margolis DJ, Chen M, Zhao X, et al
    Quality in MR reporting (include improvements in acquisition using AI).
    Br J Radiol. 2022;95:20210816.
    PubMed     Abstract available

  29. GAUDIANO C, Rustici A, Corcioni B, Ciccarese F, et al
    PI-RADS version 2.1 for the evaluation of transition zone lesions: a practical guide for radiologists.
    Br J Radiol. 2022;95:20210916.
    PubMed     Abstract available

  30. LEE CH, Vellayappan B, Tan CH
    Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis.
    Br J Radiol. 2022;95:20210509.
    PubMed     Abstract available

    February 2022
  31. KARANASIOS E, Caglic I, Zawaideh JP, Barrett T, et al
    Prostate MRI quality: clinical impact of the PI-QUAL score in prostate cancer diagnostic work-up.
    Br J Radiol. 2022 Feb 18:20211372. doi: 10.1259/bjr.20211372.
    PubMed     Abstract available

    January 2022
  32. SRITHARAN K, Tree A
    MR-guided radiotherapy for prostate cancer: state of the art and future perspectives.
    Br J Radiol. 2022 Jan 24:20210800. doi: 10.1259/bjr.20210800.
    PubMed     Abstract available

    December 2021
  33. ASLAM S, Tsang J, Bickle I, Saiepour A, et al
    Multi-parametric MRI prostate PIRAD scoring in a district general hospital: Correlating PIRADS 3 results with histological findings.
    Br J Radiol. 2021 Dec 17:20210804. doi: 10.1259/bjr.20210804.
    PubMed     Abstract available

  34. GARMER M, Karpienski J, Groenemeyer DH, Wagener B, et al
    Structured reporting in radiologic education - Potential of different PI-RADS versions in prostate MRI controlled by in-bore MR-guided biopsies.
    Br J Radiol. 2021 Dec 16:20210458. doi: 10.1259/bjr.20210458.
    PubMed     Abstract available

  35. TURKBEY B, Haider MA
    Deep learning-based artificial intelligence applications in prostate MRI: brief summary.
    Br J Radiol. 2021 Dec 3:20210563. doi: 10.1259/bjr.20210563.
    PubMed     Abstract available

    November 2021
  36. COLE AP, Langbein BJ, Giganti F, Fennessy FM, et al
    Is perfect the enemy of good? Weighing the evidence for biparametric MRI in prostate cancer.
    Br J Radiol. 2021 Nov 26:20210840. doi: 10.1259/bjr.20210840.
    PubMed     Abstract available

  37. CHO HH, Kim CK, Park H
    Overview of radiomics in prostate imaging and future directions.
    Br J Radiol. 2021 Nov 19. doi: 10.1259/bjr.20210539.
    PubMed     Abstract available

  38. LIU FY, Sheng TW, Tseng JR, Yu KJ, et al
    Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET/CT vs PET/MRI.
    Br J Radiol. 2021 Nov 12:20210728. doi: 10.1259/bjr.20210728.
    PubMed     Abstract available

  39. GIROMETTI R, Giannarini G, Panebianco V, Maresca S, et al
    Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
    Br J Radiol. 2021 Nov 11:20210886. doi: 10.1259/bjr.20210886.
    PubMed     Abstract available

  40. DIAS AB, O'Brien C, Correas JM, Ghai S, et al
    Multiparametric ultrasound and micro-ultrasound in prostate cancer: a comprehensive review.
    Br J Radiol. 2021 Nov 9:20210633. doi: 10.1259/bjr.20210633.
    PubMed     Abstract available

  41. VAN LUIJTELAAR A, Futterer JJ, Bomers JG
    Minimally invasive magnetic resonance image-guided prostate interventions.
    Br J Radiol. 2021 Nov 1:20210698. doi: 10.1259/bjr.20210698.
    PubMed     Abstract available

    October 2021
  42. DEL MONTE M, Cipollari S, Del Giudice F, Pecoraro M, et al
    MRI-directed biopsy for primary detection of prostate cancer in a population of 223 men: MRI In-Bore vs MRI-transrectal ultrasound fusion-targeted techniques.
    Br J Radiol. 2021 Oct 5:20210528. doi: 10.1259/bjr.20210528.
    PubMed     Abstract available

    September 2021
  43. DESAI S, Costa DN
    PI-RADS and Likert scales for structured reporting in multiparametric MR imaging of the prostate.
    Br J Radiol. 2021 Sep 29:20210758. doi: 10.1259/bjr.20210758.
    PubMed     Abstract available

  44. WU YY, Fan KH
    Proton therapy for prostate cancer: current state and future perspectives.
    Br J Radiol. 2021 Sep 24:20210670. doi: 10.1259/bjr.20210670.
    PubMed     Abstract available

  45. TAMADA T, Kido A, Ueda Y, Takeuchi M, et al
    Clinical impact of ultra-high b-value (3000 s/mm(2)) diffusion-weighted magnetic resonance imaging in prostate cancer at 3T: comparison with b-value of 2000 s/mm(2).
    Br J Radiol. 2021 Sep 24:20210465. doi: 10.1259/bjr.20210465.
    PubMed     Abstract available

  46. UENO Y, Tamada T, Sofue K, Murakami T, et al
    Diffusion and quantification of diffusion of prostate cancer.
    Br J Radiol. 2021 Sep 19:20210653. doi: 10.1259/bjr.20210653.
    PubMed     Abstract available

  47. SUSHENTSEV N, Caglic I, Rundo L, Kozlov V, et al
    Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression.
    Br J Radiol. 2021 Sep 19:20210842. doi: 10.1259/bjr.20210842.
    PubMed     Abstract available

  48. ZAPATERO A, Roch M, Castro Tejero P, Buchser D, et al
    MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
    Br J Radiol. 2021 Sep 19:20210683. doi: 10.1259/bjr.20210683.
    PubMed     Abstract available

    August 2021
  49. LEE YS, Choi MH, Lee YJ, Han D, et al
    Magnetic resonance fingerprinting in prostate cancer before and after contrast enhancement.
    Br J Radiol. 2021 Aug 20:20210479. doi: 10.1259/bjr.20210479.
    PubMed     Abstract available

  50. IPPOLITI S, Fletcher P, Orecchia L, Miano R, et al
    Optimal biopsy approach for detection of clinically significant prostate cancer.
    Br J Radiol. 2021 Aug 6:20210413. doi: 10.1259/bjr.20210413.
    PubMed     Abstract available

  51. CHAPET O, Udrescu C, Bin S, Decullier E, et al
    Prostate hypofractionated radiotherapy (62Gy at 3.1Gy per fraction) with injection of hyaluronic acid: final results of the RPAH1 study.
    Br J Radiol. 2021;94:20210242.
    PubMed     Abstract available

    July 2021
  52. PAXTON M, Barbalat E, Perlis N, Menezes RJ, et al
    Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer.
    Br J Radiol. 2021 Jul 29:20210414. doi: 10.1259/bjr.20210414.
    PubMed     Abstract available

  53. JAGER A, Vilanova JC, Michi M, Wijkstra H, et al
    The challenge of prostate biopsy guidance in the era of mpMRI detected lesion: ultrasound-guided versus in-bore biopsy.
    Br J Radiol. 2021 Jul 29:20210363. doi: 10.1259/bjr.20210363.
    PubMed     Abstract available

  54. ZHANG L, Jiang D, Chen C, Yang X, et al
    Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer.
    Br J Radiol. 2021 Jul 21:20210191. doi: 10.1259/bjr.20210191.
    PubMed     Abstract available

  55. BENHMIDA S, Beneux A, Udrescu C, Rouviere O, et al
    Dosimetric feasibility of stereotactic irradiation of primary prostate cancer at 5x9 Gy with a method of urethral sparing.
    Br J Radiol. 2021 Jul 20:20210142. doi: 10.1259/bjr.20210142.
    PubMed     Abstract available

  56. MAZZOLA R, Sicignano G, Cuccia F, Vitale C, et al
    Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5 T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer.
    Br J Radiol. 2021 Jul 20:20210521. doi: 10.1259/bjr.20210521.
    PubMed     Abstract available

  57. KIM Y, Park JJ, Kim CK
    Blood oxygenation level-dependent MRI at 3T for differentiating prostate cancer from benign tissue: a preliminary experience.
    Br J Radiol. 2021 Jul 8:20210461. doi: 10.1259/bjr.20210461.
    PubMed     Abstract available

  58. GIGANTI F, Allen C, Stavrinides V, Stabile A, et al
    Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease?
    Br J Radiol. 2021 Jul 8:20210321. doi: 10.1259/bjr.20210321.
    PubMed     Abstract available

  59. GIGANTI F, Kasivisvanathan V, Kirkham A, Punwani S, et al
    Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score.
    Br J Radiol. 2021 Jul 8:20210415. doi: 10.1259/bjr.20210415.
    PubMed     Abstract available

    June 2021
  60. KUMASAKA S, Motegi S, Kumasaka Y, Nishikata T, et al
    Whole-body magnetic resonance imaging (WB-MRI) with diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) in prostate cancer: Prevalence and clinical significance of incidental findings.
    Br J Radiol. 2021 Jun 11:20210459. doi: 10.1259/bjr.20210459.
    PubMed     Abstract available

  61. QUINTERO P, Cheng Y, Benoit D, Moore C, et al
    Effect of treatment planning system parameters on beam modulation complexity for treatment plans with single-layer multi-leaf collimator and dual-layer stacked multi-leaf collimator.
    Br J Radiol. 2021;94:20201011.
    PubMed     Abstract available

    April 2021
  62. BROOKS RL, McCallum HM, Pearson RA, Pilling K, et al
    Are cone beam CT image matching skills transferrable from planning CT to planning MRI for MR-only prostate radiotherapy?
    Br J Radiol. 2021 Apr 29:20210146. doi: 10.1259/bjr.20210146.
    PubMed     Abstract available

  63. URASE Y, Ueno Y, Tamada T, Sofue K, et al
    Comparison of prostate imaging reporting and data system v2.1 and 2 in transition and peripheral zones: evaluation of interreader agreement and diagnostic performance in detecting clinically significant prostate cancer.
    Br J Radiol. 2021 Apr 21:20201434. doi: 10.1259/bjr.20201434.
    PubMed     Abstract available

  64. KUO YH, Liang JA, Chen GH, Li CC, et al
    Safety of image-guided radiotherapy in definitive radiotherapy for localized prostate cancer: a population-based analysis.
    Br J Radiol. 2021 Apr 16:20200456. doi: 10.1259/bjr.20200456.
    PubMed     Abstract available

    March 2021
  65. HE X, Xiong H, Zhang H, Liu X, et al
    Value of MRI texture analysis for predicting new Gleason grade group.
    Br J Radiol. 2021 Mar 11:20210005. doi: 10.1259/bjr.20210005.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.